This site is for people with DVT, seeking comfort and information from others who understand from personal experience.
 
HomeHome  FAQFAQ  RegisterRegister  Log in  

Share | 
 

 generic Lovenox approved for DVT

View previous topic View next topic Go down 
AuthorMessage
DVT

avatar

Posts : 44
Join date : 2008-02-21

PostSubject: generic Lovenox approved for DVT   Sat Jul 24, 2010 12:26 am

this just posted a little while ago about lovenox being approved to prevent dvt.


http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Generic-Lovenox-Approved-for-Deep-Vein-Thrombosis/ArticleNewsFeed/Article/detail/680285?contextCategoryId=40159
Back to top Go down
dero
Admin
avatar

Posts : 904
Join date : 2007-12-09
Age : 57
Location : Near Ottawa, Ontario Canada.

PostSubject: Re: generic Lovenox approved for DVT   Sat Jul 24, 2010 10:58 pm

Thanks DVT,
At least this proves that somebody is working on coming up with NEW answers to fight this monster...
cheers
Back to top Go down
http://www.lifeafterdvt.forumotion.com
dero
Admin
avatar

Posts : 904
Join date : 2007-12-09
Age : 57
Location : Near Ottawa, Ontario Canada.

PostSubject: Sanofi-Aventis sues FDA over generic Lovenox approval.   Mon Aug 02, 2010 9:00 pm




Sanofi-Aventis sues FDA over generic Lovenox approval

July 29, 2010 | Yael Waknine

Washington, DC - Sanofi-Aventis, which makes enoxaparin sodium injection (Lovenox), has filed a lawsuit in federal court against the US Food and Drug Administration (FDA), seeking a reversal of the agency's recent approval for a generic formulation of the drug made by Novartis's Sandoz and codeveloped/marketed with Momenta Pharmaceuticals.

The company is charging the FDA with failure to ensure that the generic product has the same active ingredient as the reference drug.

"If not remedied, FDA's decision will cause Sanofi-Aventis irreparable harm and may result in entry into the market of a generic product that is not clinically equivalent to Lovenox with respect to safety or efficacy," the court document states.

The company also charged the agency with exceeding its authority and ignoring its own precedent regarding the approval of generic drugs that have not been fully characterized, branding the approval as "capricious and otherwise unlawful."

Statutes in the federal Food, Drug, and Cosmetic Act preclude approval of a generic formulation's abbreviated new drug application (ANDA) if additional safety and efficacy data are required, as was the case for enoxaparin injection. Such products are generally not considered fully substitutable and require submission of a full new drug application (NDA).

"By requiring Sandoz to submit immunogenicity data not contained in the Lovenox NDA and required to address FDA safety concerns, FDA exceeded its authority to approve the drug under an ANDA," explained Emmy Tsui, a spokesperson for Sanofi-Aventis. "In addition, the company believes that FDA's criteria for determining that the Sandoz drug was the same as Lovenox were arbitrary and inconsistent with prior agency precedent."

In a news release issued on the July 23, 2010 approval date, the FDA declared that its action was consistent with current scientific evidence, precedent, and the agency's legal authority.

FDA officials remarked that although the naturally sourced drug product has some degree of batch-to-batch variability and its active ingredient has not been fully characterized, "sameness" can be demonstrated by comparing five specific molecular criteria.

"Before approving generic enoxaparin sodium injection, we expected, among other things, a series of sophisticated analytical tests and a study in healthy volunteers to ensure that the drug would be as safe and effective as the brand name product," said Dr Keith Webber, deputy director of the FDA's Office of Pharmaceutical Science, in an agency news release.

According to Sanofi-Aventis, however, these data are not sufficient to garner approval for generic enoxaparin; head-to-head clinical trials with the reference drug should be required as part of an NDA.

Thus far, Sanofi-Aventis has not succeeded in halting sales of generic enoxaparin.

In a status conference held by the US District Court for the District of Columbia on July 26, 2010, the Hon Emmet G Sullivan denied the company's request for a restraining order to stop sales of the product, which began shipping immediately on approval. A hearing to consider a preliminary injunction has been scheduled for August 17, 2010, Momenta officials said in a news release.

This is only the latest chapter in Sanofi-Aventis's attempts to block a generic enoxaparin competitor. In 2007, a district court ruled that the Lovenox patents were unenforceable, a decision upheld the following year. Last year, a key Lovenox patent was voided after the US Supreme Court ruled that the company had misled the US Patent and Trademark Office.
Back to top Go down
http://www.lifeafterdvt.forumotion.com
Sponsored content




PostSubject: Re: generic Lovenox approved for DVT   

Back to top Go down
 
generic Lovenox approved for DVT
View previous topic View next topic Back to top 
Page 1 of 1

Permissions in this forum:You cannot reply to topics in this forum
Life DOES go on after DVT :: Why does this forum exist??? :: News in the world.-
Jump to: